Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...

HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...

HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...

The S&P 500’s health care sector (NYSEARCA:XLV), holding a weightage of 12.12% in the S&P 500 index, saw a fall of 10.2% in ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...

Vertex has appointed a new commercial head for ex-US activites, as the company aims to resolve its two-year row with UK health officials over the price of its cystic fibrosis drugs.

and Vertex’s chief scientific officer David Altshuler has joined the UK firm’s board. Humana to invest in digital health US health firm Humana is to expand its capability in technology ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $416.96, moving -1.72% from the previous trading session.

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $456 from $476 and keeps an Equal ...

Vertex Pharmaceuticals has a new drug called suzetrigine that it says is nonaddictive and would offer an alternative to painkillers such as oxycodone. The company’s application is pending before the ...

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell disease and transfusion-dependent beta thalassemia.